title: The effects of rosiglitazone, metformin, and diet with exercise in nonalcoholic fatty liver disease.
abstract: Our aim was to evaluate effects of metformin, rosiglitazone, and diet with exercise in nonalcoholic fatty liver disease. Forty-seven patients (mean age, 44+/-10 years; 17 female) whose ALT levels had been high for at least 6 months and with hepatosteatosis detected by liver biopsy and/or USG were enrolled in this study. Of these, 12 were treated with 850 mg/day metformin (group 1), 11 with 4 mg/day rosiglitazone (group 2), and 24 with diet and exercise (group 3) for 1 year. ALT normalization at months 6 and 12 was accepted as treatment response. Liver biopsy was performed in all patients in groups 1 and 2 before treatment and 12 patients (4 in group 1, 8 in group 2) after treatment; but in group 3 it was performed only in patients who approved this procedure (12 patients). Body mass index did not change in groups 1 and 2, but it decreased significantly in group 3 (30+/-3 to 28+/-2 kg/m(2)) at month 12. Treatment response rate was 33.3, 54.5, and 54.2% in groups 1, 2, and 3, respectively, at month 6. This rate was 22.2, 37.5, and 41.2 in groups 1, 2, and 3, respectively, at month 12. Rate of steatosis and stage of fibrosis did not change after treatment. Diet with exercise seems to be superior to metformin and rosiglitazone. Decreasing treatment response at month 12 compared to month 6 may be due to fluctuations of ALT levels. Treatment response should be evaluated histologically.
authors: Department of Gastroenterohepatology Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey.
authors: Filiz
authors: F
authors: Akyüz
authors: Kadir
authors: K
authors: Demir
authors: Sadakat
authors: S
authors: Ozdil
authors: Nevzat
authors: N
authors: Aksoy
authors: Sule
authors: S
authors: Poturoğlu
authors: Duygu
authors: D
authors: Ibrişim
authors: Sabahattin
authors: S
authors: Kaymakoğlu
authors: Fatih
authors: F
authors: Beşişik
authors: Güngör
authors: G
authors: Boztaş
authors: Yilmaz
authors: Y
authors: Cakaloğlu
authors: Zeynel
authors: Z
authors: Mungan
authors: Uğur
authors: U
authors: Cevikbaş
authors: Atilla
authors: A
authors: Okten
mesh_terms: D000328:Adult; D001706:Biopsy; D018752:Diet, Fat-Restricted; D004305:Dose-Response Relationship, Drug; D005081:Exercise Therapy; D005234:Fatty Liver / Q000201:enzymology / Q000473:pathology / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008687:Metformin / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000008:administration & dosage / Q000627:therapeutic use*; D000637:Transaminases / Q000097:blood; D016896:Treatment Outcome; D014665:Vasodilator Agents
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D014665:Vasodilator Agents; D000077154:Rosiglitazone; D008687:Metformin; D000637:Transaminases